Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Frontiers in Genetics|November 7, 2025
Single-cell transcriptomics in metastatic breast cancer: mapping tumor evolution and therapeutic resistanceXu Han, Xin Li, Ling Bai, et al.Cancer Management and Research|February 25, 2022
Integrative Analysis of Peripheral Blood Indices for the Renal Sinus Invasion Prediction of T1 Renal Cell Carcinoma: An Ensemble Study Using Machine Learning-Assisted Decision-Support ModelsXin Li, Bo Liu, Peng Cui, et al.Frontiers in Oncology|August 18, 2025
Regulation of sphingolipid metabolism in the immune microenvironment of gastric cancer: current insights and future directionsYunqi Hua, Gangling Zhang, Yubo Liu, et al.Talanta|October 16, 2025
A stretching-state DNA triangular prism based electrochemical biosensor for rapid and sensitive microRNA detectionFei Yu, Gangling Zhang, Haimai Ding, et al.JCO Precision Oncology|January 18, 2023
Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical TrialLiulu Zhang, Zhiyong Wu, Jie Li, et al.International Journal of Cancer|September 30, 2021
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trialLiulu Zhang, Zhi-Yong Wu, Jie Li, et al.Therapeutic Advances in Medical Oncology|May 7, 2021
Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trialHong-Fei Gao, Zhiyong Wu, Ying Lin, et al.Nature Communications|November 17, 2022
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancerNan Niu, Fang Qiu, Qianshi Xu, et al.Pageof 1